TD-9855
Phase 2Small molecule
TD-9855 is one of 63 small molecule programs targeting Orthostatic Hypotension. It is currently in Phase 2.
2
Indications
5
Total Trials
0
Active Trials
62
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
152 competitors in Fibromyalgia
#DrugCompanyPhaseTrials
1Xyrem
Jazz PharmaceuticalsPhase 3
Namenda
AbbViePhase 3
Epidiolex
Jazz PharmaceuticalsPhase 3
Neurontin
VViatris Specialty LLC
Phase 3
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Ultram
WWim Janssens
Phase 3
DS-5565
Daiichi SankyoPhase 3
Genotropin
EMD SeronoPhase 3
Feosol
AAuerbach Hematology Oncology Associates P C
Phase 3
Saizen
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Attention Deficit Hyperactivity Disorder1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TD-9855. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TTheravance Biopharma